Directory

Spark Impact


The NW Fund for Biomedical has been a very active healthcare-sector investor in the last 4 years, but this fund is now closed to new projects. New EU funds will be launched in Q2 2017. Before then, the new Catapult Life Sciences Fund is the place to look for projects with a healthcare angle.


£500k – £2m


Technology, Media and Telecoms


Businesses turning over above £1m revenues p.a. Funding for growth.


>_fund:tmt’s Fund I at £5.0m.


>_fund:tmt is a newly raised Private Equity fund managed by Spark Impact Limited, current Fund Managers of the North West Fund For Biomedical and Scheme Managers of the Isle of Man’s Enterprise Development Scheme.

“We are a new Technology, Media and Telecoms (TMT) focussed equity fund, who seek to invest in backable entrepreneurs with scalable business models. By catering solely to the TMT sector, we can add specific expertise to help companies as they grow and fulfil entrepreneurial ambitions. We have no specific areas of TMT that are off limits, whilst our flexible fund structure means we can accommodate any type of transaction.”


Our main criteria for investment are detailed below:
–      £1m+ revenues per year
–      A level of recurring of repeatable revenues
–      UK based
–      Technology, Media & Telecoms sector
–      Owner managed
–      Clear exit route for the fund
–      £0.5m to £1m investments (at present)


An Investment Committee decision to invest leads to a formal offer to the potential investee company in the form of a Term Sheet. This is complimented by our TMT specific Advisory Board, who can help add-value to both the deal team and the business throughout the life of the relationship.


Example companies


Alderley Analytical

Alderley Analytical provides bioanalytical services to support the development of small and large molecule therapeutics, generics and biomarkers in all stages of the drug development process.

Why they invested

The management team of Alderley Analytical comprises highly experienced individuals with a combined total of over 100 years in the industry and significant experience in Contract Research Organizations (performing Bioanalytical services) or in Large Pharma, managing external outsourcing of such contracts.

 

Videregen

A spin-out regenerative medicine company from Northwick Park Institute of Medical Research (London, UK) created to address the chronic shortage of organs for transplantation. The company’s core technology uses decellularised organ scaffolds seeded with the patient’s own stem cells to create non-immunogenic, regenerative bespoke organ replacements.

Why they invested

The technology developed by Videregen to make functional organs for transplant is expected to show clear benefits as a potentially globally disruptive form of regenerative medicine.